• Advancing gastrointestinal health naturally

    Our Gastrointestinal Reprogramming Product (GaRP) product is a microbiome-targeted multi-component dietary supplement that has been designed to address the primary underlying factors associated with gastrointestinal disorders.

  • Exclusive Global License Agreement with Zoetis

    Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. More >>

Company description

Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach is a natural product that has been shown to aid in the control of scour in piglets. Anatara has signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.

Video overview

Latest news All news

  • Appendix 3B

    Anatara Lifesciences is pleased to release its Appendix 3B – New issue announcement, for the issue of 750,000 options issued to Peloton Capital for Corporate Advisory Services, as announced to the market on 29th August 2018.

    Please click here to view the ASX announcement.

  • Initial Director’s Interest Notice

    Anatara Lifesciences have issued an Appendix 3X, advising the ASX that Jane Ryan was appointed a director as of 1 September 2018.

    Please click here for the ASX announcement.

Investors

Investors Home

Pause